194 related articles for article (PubMed ID: 24855280)
1. Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.
van den Brand JA; van Dijk PR; Hofstra JM; Wetzels JF
Clin J Am Soc Nephrol; 2014 Jun; 9(6):1066-73. PubMed ID: 24855280
[TBL] [Abstract][Full Text] [Related]
2. Malignancy in Renal Transplant Recipients Exposed to Cyclophosphamide Prior to Transplantation for the Treatment of Native Glomerular Disease.
Jorgenson MR; Descourouez JL; Singh T; Astor BC; Panzer SE
Pharmacotherapy; 2018 Jan; 38(1):51-57. PubMed ID: 29136299
[TBL] [Abstract][Full Text] [Related]
3. Balancing cancer risk and efficacy of using cyclophosphamide to treat idiopathic membranous nephropathy.
Khan S; Bolton WK
Clin J Am Soc Nephrol; 2014 Jun; 9(6):1001-4. PubMed ID: 24855281
[No Abstract] [Full Text] [Related]
4. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.
van den Brand JAJG; Ruggenenti P; Chianca A; Hofstra JM; Perna A; Ruggiero B; Wetzels JFM; Remuzzi G
J Am Soc Nephrol; 2017 Sep; 28(9):2729-2737. PubMed ID: 28487395
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.
Cortazar FB; Leaf DE; Owens CT; Laliberte K; Pendergraft WF; Niles JL
BMC Nephrol; 2017 Feb; 18(1):44. PubMed ID: 28143416
[TBL] [Abstract][Full Text] [Related]
6. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial.
Hofstra JM; Branten AJ; Wirtz JJ; Noordzij TC; du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2010 Jan; 25(1):129-36. PubMed ID: 19666912
[TBL] [Abstract][Full Text] [Related]
7. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.
Hoxha E; Harendza S; Pinnschmidt H; Panzer U; Stahl RA
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1883-90. PubMed ID: 25267554
[TBL] [Abstract][Full Text] [Related]
8. Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study.
van de Logt AE; Beerenhout CH; Brink HS; van de Kerkhof JJ; Wetzels JF; Hofstra JM
PLoS One; 2015; 10(11):e0142033. PubMed ID: 26562836
[TBL] [Abstract][Full Text] [Related]
9. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.
Branten AJ; Wetzels JF
Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: A retrospective cohort study.
Xie Z; Dong W; Li Z; Chen Y; Song L; Li R; Wu Y; Fu L; Liang H; Tao Y; Xie J; Wang W; Liu S; Ye Z; Shi W; Liang X
Nephrology (Carlton); 2020 Mar; 25(3):219-229. PubMed ID: 31900967
[TBL] [Abstract][Full Text] [Related]
11. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.
Jha V; Ganguli A; Saha TK; Kohli HS; Sud K; Gupta KL; Joshi K; Sakhuja V
J Am Soc Nephrol; 2007 Jun; 18(6):1899-904. PubMed ID: 17494881
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy.
Zou H; Jiang F; Xu G
Ren Fail; 2019 Nov; 41(1):673-681. PubMed ID: 31354007
[No Abstract] [Full Text] [Related]
13. A 10-year follow-up of idiopathic membranous nephropathy patients on steroids and cyclophosphamide: a case series.
Ram R; Guditi S; Kaligotla Venkata D
Ren Fail; 2015 Apr; 37(3):452-5. PubMed ID: 25594615
[TBL] [Abstract][Full Text] [Related]
14. Treatment of nephrotic idiopathic membranous nephropathy with monthly i.v. pulse cyclophosphamide and oral steroids: a single centre's retrospective study.
Yuan J; Fang W; Zhang W; Ni Z; Qian J
Nephrology (Carlton); 2011 May; 16(4):440-5. PubMed ID: 21091923
[TBL] [Abstract][Full Text] [Related]
15. Clinical features, course and prognosis of idiopathic membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor.
Jatem Escalante E; Segarra Medrano A; Carnicer Cáceres C; Martín-Gómez MA; Salcedo Allende MT; Ostos Roldan H; Agraz Pamplona I
Nefrologia; 2015; 35(5):479-86. PubMed ID: 26306972
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity.
du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2004 Aug; 19(8):2036-43. PubMed ID: 15187191
[TBL] [Abstract][Full Text] [Related]
17. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.
Ponticelli C; Altieri P; Scolari F; Passerini P; Roccatello D; Cesana B; Melis P; Valzorio B; Sasdelli M; Pasquali S; Pozzi C; Piccoli G; Lupo A; Segagni S; Antonucci F; Dugo M; Minari M; Scalia A; Pedrini L; Pisano G; Grassi C; Farina M; Bellazzi R
J Am Soc Nephrol; 1998 Mar; 9(3):444-50. PubMed ID: 9513907
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS
Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological Features of Idiopathic Membranous Nephropathy in 33 Adolescents.
Li C; Li H; Wen YB; Li JN; Lin WF; Cai JF; Duan L; Li Y; Li XM; Li XW
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):544-551. PubMed ID: 28877834
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone.
Eriguchi M; Oka H; Mizobuchi T; Kamimura T; Sugawara K; Harada A
Nephrol Dial Transplant; 2009 Oct; 24(10):3082-8. PubMed ID: 19465558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
